- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 65666-07-1] Silymarin
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-N7073 |
| Brand: | MCE |
| CAS: | 65666-07-1 |
Overview
| MDL | MFCD00872186 |
|---|---|
| Molecular Weight | - |
| Molecular Formula | Unspecified |
| SMILES | [Silymarin] |
3 Publications Citing Use of MCE
Summary
Silymarin is an extract of the milk thistle ( Silybum marianum ). Silymarin is an effective SARS-CoV-2 main protease (M pro ) inhibitor. Silymarin can significantly reduce tumor cell proliferation, angiogenesis as well as insulin resistance. Silymarin has the chemopreventive effect on hepatocellular carcinoma (HCC). Silymarin has the potential for COVID-19 research [1] [2] [4] .
In Vitro
Silymarin (0-120 µg/ml; 24 hours) inhibits AGS cell viability, the viability of AGS cells is 77.9% in the presence of 20 µg/ml silymarin, 71.5% at 40 µg/ml, 59.8% at 60 µg/ml, 44.5% at 80 µg/ml, 35.3% at 100 µg/ml and 33.9% at 120 µg/ml
[1]
.
Silymarin (40-80 µg/ml; 24 hours) inhibits the migration of the AGS cells in a concentration-dependent manner. It inhibit migration of AGS cells 59.4% at 40 µg/ml and 21.7% at 80 µg/ml,respectively
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [2]
| Cell Line: | AGS cells |
| Concentration: | 20 µg/ml, 40 µg/ml, 80 µg/ml, 100 µg/ml and 120 µg/ml |
| Incubation Time: | 24 hours |
| Result: | Indicated a significant concentration-dependent inhibitory effect on AGS cells starting at 20 µg/ml. |
In Vivo
Silymarin (oral gavage; 10, 20, 50, 100, and 200 mg/kg) decreases the immobility time in a dose-dependent manner in forced swimming test (FST). It also lowers the immobility measure dose-dependently in tail suspension test (TST). Additionally, 50% of maximum response (ED 50 ) of Silymarin is around 10 mg/kg. The dose 100 mg/kg proved the most effective dose in both the tests [3] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT04816682 | F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica |
Covid19|Liver Diseases
|
March 17, 2021 | Phase 4 |
| NCT00065741 | National Center for Complementary and Integrative Health (NCCIH) |
HIV Seronegativity
|
September 2003 | Phase 1 |
| NCT03174561 | SC Fiterman Pharma SRL |
Irritable Bowel Syndrome
|
May 1, 2017 | Not Applicable |
| NCT00755950 | University of Maryland, Baltimore|MADAUS GmbH|The Egyptian Company for Blood Transfusion Services|Tanta Fever Hospital|Banha Fever Hospital|Alexandria University |
Acute Hepatitis A|Acute Hepatitis B|Acute Hepatitis C|Acute Hepatitis E|Acute EBV Hepatitis|Acute CMV Hepatitis
|
October 2008 | Phase 2|Phase 3 |
| NCT02878863 | Xiaoli Fan|West China Hospital |
Hepatitis, Autoimmune
|
August 2016 | Phase 3 |
| NCT01258686 | Bukwang Pharmaceutical |
Hepatitis C
|
November 2010 | Phase 3 |
| NCT03982849 | Islamabad Medical and Dental College |
Melasma
|
July 15, 2019 | Phase 2 |
| NCT01436929 | Seoul National University Hospital |
Tuberculosis
|
September 2011 | Not Applicable |
| NCT05099601 | Assiut University |
Melasma
|
May 2022 | Phase 4 |
| NCT01800487 | Ramathibodi Hospital |
Tuberculosis
|
January 2012 | Not Applicable |
| NCT03659058 | Zagazig University |
Fibrosis, Liver
|
March 2, 2016 | Not Applicable |
| NCT03547895 | Zagazig University |
Decompensated Cirrhosis
|
June 1, 2015 | Not Applicable |
| NCT00389376 | National Center for Complementary and Integrative Health (NCCIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
Hepatitis C|Non-Alcoholic Fatty Liver Disease
|
November 2006 | Phase 1 |
| NCT04490967 | Assiut University |
Acne Vulgaris
|
April 2021 | Phase 4 |
| NCT00680342 | National Center for Complementary and Integrative Health (NCCIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Pennsylvania|University of North Carolina, Chapel Hill|Thomas Jefferson University|Beth Israel Deaconess Medical Center|University of Pittsburgh |
Chronic Hepatitis C
|
April 2008 | Phase 2 |
| NCT03130634 | Kaohsiung Medical University Chung-Ho Memorial Hospital |
Metastatic Colorectal Cancer
|
April 2016 | Phase 4 |
| NCT01018615 | University of North Carolina, Chapel Hill|National Center for Complementary and Integrative Health (NCCIH)|National Institutes of Health (NIH) |
Chronic Hepatitis C|Oxidative Stress
|
November 2009 | Phase 1 |
| NCT00055718 | Herbert Irving Comprehensive Cancer Center|National Cancer Institute (NCI) |
Drug+Agent Toxicity by Tissue+Organ|Leukemia
|
November 2001 | Phase 2 |
| NCT01752153 | Shiraz University of Medical Sciences |
Immune Abnormalities
|
June 2012 | Phase 1 |
| NCT05042245 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|First Affiliated Hospital, Sun Yat-Sen University|Beijing Ditan Hospital|Beijing YouAn Hospital|Wuhan Union Hospital, China |
Non-alcoholic Fatty Liver Disease
|
April 26, 2019 | Phase 4 |
| NCT00412763 | University of Maryland, Baltimore |
Hepatitis
|
July 2003 | Phase 4 |
| NCT00011635 | National Institutes of Health Clinical Center (CC) |
HIV Infection|Healthy
|
February 2001 | Phase 1 |
| NCT04810572 | University of Sao Paulo General Hospital|University of Sao Paulo |
Insulin Resistance|Inflammatory Bowel Diseases|Overweight and Obesity|Healthy
|
May 20, 2021 | Not Applicable |
| NCT01829178 | Tehran University of Medical Sciences |
Upper GI Cancer|Cisplatin Adverse Reaction
|
August 2013 | Phase 2|Phase 3 |
| NCT00680407 | Madaus Inc|University of Pennsylvania|University of North Carolina|Thomas Jefferson University|Beth Israel Deaconess Medical Center|Brooke Army Medical Center|University of Pittsburgh |
Non-alcoholic Steatohepatitis
|
April 2008 | Phase 2 |
| NCT01292161 | Isfahan University of Medical Sciences |
Hepatitis C
|
March 2006 | Phase 2 |
| NCT02973295 | University Hospital Rijeka|University of Rijeka, Medical Faculty|Belupo|University of Rijeka, Faculty of Health studies |
Non-Alcoholic Fatty Liver Disease
|
September 20, 2019 | Phase 4 |
| NCT04394208 | Cairo University |
COVID-19|Viral Pneumonia Human Coronavirus
|
August 16, 2020 | Phase 3 |
| NCT05595109 | Tanta University |
Breast Cancer|Peripheral Neuropathy|Cardiac Toxicities|Hepatic Toxicity|Cognitive Impairment
|
October 28, 2022 | Phase 2|Phase 3 |
| NCT00999349 | Isfahan University of Medical Sciences|Madaus Inc |
Beta-thalassemia Major|Iron Overload
|
March 2009 | Phase 2|Phase 3 |
| NCT01091324 | National Cheng-Kung University Hospital |
Proteinuria
|
January 2010 | Phase 3 |
| NCT03749070 | Camila Ribeiro de Avelar|Hospital Universitário Professor Edgard Santos |
Non-Alcoholic Fatty Liver Disease
|
February 15, 2019 | Not Applicable |
| NCT00030030 | National Center for Complementary and Integrative Health (NCCIH)|Office of Dietary Supplements (ODS) |
Hepatitis C, Chronic
|
July 2000 | Phase 2 |
| NCT00246363 | Henry Sacks|National Institute of Nursing Research (NINR)|Icahn School of Medicine at Mount Sinai |
HIV Infections|Hepatitis C
|
January 2005 | Phase 1|Phase 2 |
| NCT01049178 | Vanderbilt University |
Atopic Asthma
|
September 2010 | Phase 2|Phase 3 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
References
- [1] Féher J, et al. Silymarin in the prevention and treatment of liver diseases and primary liver cancer. Curr Pharm Biotechnol. 2012 Jan;13(1):210-7.
- [2] Sung-Hyun Kim, et al.Silymarin induces inhibition of growth and apoptosis through modulation of the MAPK signaling pathway in AGS human gastric cancer cells. Oncol Rep. 2019 Nov;42(5):1904-1914.
- [3] Mina Khoshnoodi, et al. Possible involvement of nitric oxide in antidepressant-like effect of silymarin in male mice. Pharm Biol. 2015 May;53(5):739-45.
- [4] Anna Maria Sardanelli, et al. SARS-CoV-2 Main Protease Active Site Ligands in the Human Metabolome. Molecules 2021, 26(5), 1409.
Synonyms
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.